Dutch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
10 resultaten
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
The present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to bioisosteres of quinoline and quinazoline derivatives which exhibit protein
Tyrosine amide derivatives as Rho-kinase inhibitors
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
CROSS REFERENCES TO RELATED APPLICATIONS
This application claims priority to European Patent Application No. 17153785.5 filed on Jan. 30, 2017, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds
Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
Hepatocyte growth factor (HGF) has anti-fibrogenic properties. However, several studies have shown that HGF only affects fibroblasts expressing the HGF receptor known as cellular mesenchymal-epithelial transition factor (c-MET, MET). During fibrotic diseases, such as
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for making the compounds, and to the use of the compounds in therapy. More particularly, it relates to certain substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for making the compounds, and to the use of the compounds in therapy. More particularly, it relates to certain substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for making the compounds, and to the use of the compounds in therapy. More particularly, it relates to certain substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide
Naphthyridine derivatives and the use thereof as kinase inhibitors
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
TECHNICAL FIELD
The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
Fibrosis is an intermediate result of and a pathological process itself leading from tissue injury through its encapsulation by extracellular matrix to a pathological formation of scar tissue.
Injury leading to fibrosis occurs in response to a variety of chronic insults
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
Fibrosis is an intermediate result of and a pathological process itself leading from tissue injury through its encapsulation by extracellular matrix to a pathological formation of scar tissue.
Injury leading to fibrosis occurs in response to a variety of chronic insults
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
Fibrosis is an intermediate result of and a pathological process itself leading from tissue injury through its encapsulation by extracellular matrix to a pathological formation of scar tissue.
Injury leading to fibrosis occurs in response to a variety of chronic insults
De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap
- Werkt in 55 talen
- Kruidengeneesmiddelen gesteund door de wetenschap
- Kruidenherkenning door beeld
- Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
- Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
- Zoek medicinale kruiden op hun effecten
- Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten
Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek
